Skip to main content
. 2020 Jan 14;11:259. doi: 10.1038/s41467-019-13689-y

Fig. 4. STING-dependent induction of TNFα and type I IFN triggers a proapoptotic secretome.

Fig. 4

a–c IFNB1 and TNF qPCR analysis in LMNB2 overexpressing (a), STING −/− (b) or cGAS −/− (c) and control MDA-MB-468 cells after 24 h paclitaxel treatment. d IFNα production before and after paclitaxel treatment in control or STING−/− MDA-MB-468 cells. e TNF, IFNB1 and PMAIP1 qPCR analysis in BC-PDX #306 and BC-PDX #248 after a 48 h-treatment by the STING agonist diABZI. f 24 h-paclitaxel-treated or not (donor) cells were washed out to produce 48 h-conditioned media (CM) that were applied to untreated (recipient) IFNAR1 −/− cancer cells for 48 h in presence or not of the BH3 mimetic WEHI-539. Apoptotic index in recipient breast cancer cells was assessed using Annexin-V staining. IFNAR1 expression was detected by cytometry after immunostaining (right panel). g Same experiment as (f) using control or TNFα−/− MDA-MB-468 donor cells and TNFα expression was detected by immunoblot analysis in monensin-treated cells for 72 h after 24 h paclitaxel treatment or not (right panel). h Same experiment as (f) using TNFα blocking antibody preincubated in CM before addition to MDA-MB-468 (left) or MDA-MB-231 (right) recipient cells. i Apoptotic effect of recombinant IFNα and/or TNFα on MDA-MB-468 cells treated or not with WEHI-539 during 48 h. Data were collected from at least n = 3 independent experiments. Error bars indicate mean +/− SEM; Two-sided paired t-test. The symbols correspond to a p-value inferior to *0.05 and **0.01.